Eyepoint Pharmaceuticals Inc. shares dropped to a 52-week low of $4.06 on Tuesday, marking the company’s weakest valuation since mid-2023.
The decline extends a prolonged downturn for the biotechnology sector, which has faced investor skepticism amid rising interest rates, regulatory scrutiny and funding challenges. Eyepoint, a developer of ophthalmic treatments, has also contended with company-specific headwinds, including pipeline delays and commercial execution risks.
Trading volume spiked to roughly 1.2 million shares, nearly triple the 30-day average, as investors reassessed the company’s near-term prospects. The stock last traded at $4.12, down 1.4% in midday trading, following a 5.2% drop on Monday.
Analysts cited limited visibility into Eyepoint’s revenue trajectory as a key driver of the sell-off. The company has not provided updated financial guidance since its last earnings report in November 2023, when it reported a net loss of $0.89 per share on revenue of $12.3 million.
The broader biotech index, as measured by the SPDR S&P Biotech ETF, has fallen nearly 12% year-to-date, reflecting broader sector malaise. Eyepoint’s market capitalization now stands at approximately $220 million, down from $380 million at the start of 2024.
The company’s lead product, DEXTENZA, an ocular steroid implant for post-surgical inflammation, has faced slower-than-expected adoption in ophthalmology clinics. Competing therapies and pricing pressures have further constrained revenue growth.
Eyepoint has not responded to requests for comment on the stock’s decline or its strategic plans.
